Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 5,758 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Diseases Clear all
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

NCT06616766
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Interventions
YH42946
Drug
Lead sponsor
Yuhan Corporation
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257
View directory record Official record
Conditions
Limited-Stage Small Cell Lung Cancer
Interventions
HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Drug · Radiation
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
31
States / cities
Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110
View directory record Official record
Conditions
Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma, Renal Cell Carcinoma
Interventions
GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 5, 2026, 2:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing a Shared Decision Making Tool for Patients With Surgically Removed Non-small Cell Lung Cancer

NCT05416983
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Discussion, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 5, 2026, 2:39 PM EDT
Recruiting No phase listed Observational

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

NCT05537922
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Adenocarcinoma
Interventions
Not listed
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 5, 2026, 2:39 PM EDT
Active, not recruiting No phase listed Observational

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

NCT05250037
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Home spirometry, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
8 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782
View directory record Official record
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements

NCT03534986
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage, Electromed SmartVest
Device
Lead sponsor
International Biophysics Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Kissimmee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

NCT01716754
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Omalizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Levalbuterol HFA Compared to Racemic Albuterol HFA in Subjects With Asthma

NCT00685022
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI, Racemic Albuterol followed by levalbuterol HFA MDI
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
3
States / cities
Encinitas, California • North Dartmouth, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 5, 2026, 2:39 PM EDT
Withdrawn No phase listed Observational

Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation

NCT01631760
View directory record Official record
Conditions
Asthma
Interventions
no intervention
Genetic
Lead sponsor
University of South Florida
Other
Eligibility
5 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters

NCT05615870
View directory record Official record
Conditions
Bronchiolitis
Interventions
Winix 5500-2 HEPA filtration units
Other
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
1 Week to 12 Months
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Honolulu, Hawaii + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

A Multifaceted Prompting Intervention for Urban Children With Asthma

NCT01105754
View directory record Official record
Conditions
Asthma
Interventions
Multifaceted Prompting Intervention MPI
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 12 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

NCT00362882
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
docetaxel, bortezomib, laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 5, 2026, 2:39 PM EDT
Completed No phase listed Observational

A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer

NCT03616522
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
a novel mobile phone-based intervention for automated electronic PRO collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 4 Interventional

Onset and Duration of Mometasone by Oscillometry and Spirometry

NCT01635088
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate 220, KoKo Spirometry, Mometasone furoate 440, Oscillometry
Drug · Device
Lead sponsor
California Allergy and Asthma Medical Group, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 5, 2026, 2:39 PM EDT
Recruiting Phase 1 Interventional

Gilteritinib for the Treatment of ALK NSCLC

NCT06225427
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Phase 3 Interventional

Predicting the Response to Montelukast by Genetic Variation in Asthmatics

NCT00116324
View directory record Official record
Conditions
Asthma
Interventions
Montelukast
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 5, 2026, 2:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbes and Respiratory Illnesses

NCT06059027
View directory record Official record
Conditions
Virus, Asthma
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years to 12 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 5, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

NCT01803269
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
topotecan hydrochloride, cyclodextrin-based polymer-camptothecin CRLX101
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 5, 2026, 2:39 PM EDT
Completed No phase listed Observational

Bion Occipital Nerve Stimulation (ONS) Compassionate Use Study

NCT01050959
View directory record Official record
Conditions
Chronic, Medically Refractory Headache
Interventions
bion
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Phoenix, Arizona • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 5, 2026, 2:39 PM EDT
Completed No phase listed Observational

Oral Bacteria and Allergic Disease in Children

NCT00438646
View directory record Official record
Conditions
Asthma, Rhinitis, Eczema, Respiratory Sounds, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 5, 2026, 2:39 PM EDT
Completed Not applicable Interventional

Effect of CPAP (Continuous Positive Airway Pressure) on Lung Function in Asthmatics With Sleep Apnea

NCT00238069
View directory record Official record
Conditions
Asthma, Sleep Apnea
Interventions
CPAP machine as a result of sleep study
Device
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 5, 2026, 2:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379
View directory record Official record
Conditions
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 2:39 PM EDT